Effect of Erythropoietin in Patients with Acute Myocardial Infarction: Five-Year Results of the REVIVAL-3 Trial
Erythropoietin (EPO) has been suggested to promote cardiac repair after MI. However, the randomized, double-blind, placebo controlled REVIVAL-3 trial showed that short term high dose EPO in timely reperfused myocardium does not improve left ventricular ejection fraction after 6 months.